{"success":true,"data":{"pressRelease":{"id":"140308","rtpr_id":"nBw5ZmWQwa-20260910","ticker":"DNA","exchange":"NYSE","all_tickers":["DNA"],"title":"Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines","author":"Business Wire","published_at":"2026-09-10T12:00:02.212Z","article_body":"Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing\nSystem for Individualized RNA Medicines\n\nGinkgo plans to build the automation hardware and control software for\nESCALATOR, a continuous-flow, autonomous manufacturing system designed to\nproduce and quality-release RNA drug products at patient scale\n\nGinkgo Bioworks (NYSE: DNA) today announced that it has been awarded a\nsubcontract for up to $17.5M under the Advanced Research Projects Agency for\nHealth’s (ARPA-H) Genetic Medicines and Individualized Manufacturing for\nEveryone (GIVE) program. Ginkgo will serve as a subcontractor to prime\ncontractor Waterfall Scientific, Inc. on ESCALATOR (Engineering a Small-scale,\nContinuous-flow manufacturing Apparatus to Launch A Transformational Overhaul\nfor RNA medicines), a multi-organization effort to compress end-to-end RNA\ndrug manufacturing onto a benchtop footprint.\n\nRNA therapeutics designed for a single patient—including individualized\ncancer vaccines and bespoke gene therapies—remain difficult to deliver at\nscale. Production today depends on large, centralized facilities, lengthy\nmanual workflows, and quality control processes that were designed for batch\nsizes far larger than one. The result is a class of medicine that is\nscientifically feasible but logistically out of reach for most patients who\ncould benefit from it.\n\nESCALATOR is designed to change that equation by building a single,\nintegrated, autonomous manufacturing system that accepts a sequence and\nreturns a purified, quality-released RNA drug product at the scale an\nindividual patient requires. The system comprises four custom manufacturing\nmodules: cell-free DNA template production, RNA synthesis, lipid nanoparticle\n(LNP) encapsulation, and fill and finish. These are coupled to an in-line\nquality control subsystem drawing on approximately twenty analytical\ninstruments.\n\nGinkgo’s Role: Making Twenty Instruments Behave as One System\n\nGinkgo is building the layer that turns a collection of instruments into an\nintegrated autonomous manufacturing system and carries the process through to\nan automated quality decision on the finished product. Drawing on its\nReconfigurable Automation Carts (RACs) and Catalyst software, Ginkgo aims to:\n\n\n * Integrate the four custom manufacturing modules and the quality control\ninstrument set into a unified robotic transport platform;\n\n * Extend Catalyst to control the entire system with a unified interface,\nproviding simple local configuration and launching of manufacturing runs,\nremote protocol definition and monitoring, and the data integrity and audit\ntrail expected of GMP manufacturing environments;\n\n * Develop and validate automated protocols for both the manufacturing and\nquality control workflows, including virtual protocol simulation prior to\nhardware execution; and\n\n * Enable Catalyst to rigorously evaluate product quality based on data collected\nby the system and historical benchmarks, escalating to expert review as\nappropriate.\n\n“One of the most challenging parts of ESCALATOR is making instruments from\nsix different organizations behave as one controlled, auditable system that a\ntrained technician can operate without a robotics team standing behind\nthem,” said Jason Kelly, co-founder and CEO at Ginkgo Bioworks. \"Ginkgo has\nspent years building autonomous labs that can work with a variety of hardware\nand with proprietary software that tracks every device for every run.\nDistributed manufacturing has stayed a promise rather than a practice because\nthat layer didn’t exist. We are excited to be deploying it for ESCALATOR.”\n\n\"We are thrilled to lead such an exceptional consortium on this journey to\nmake personalized medicine a reality for patients who cannot wait. Ginkgo\nBioworks brings unmatched hardware and software integration capabilities to\nthe table, and we look forward to building a truly transformative system\ntogether,” said Inna Shcherbakova, co-founder and CEO of Waterfall\nScientific.\n\nA Consortium Assembled Around a Single Integrated System\n\nThe ESCALATOR team brings together six organizations across the United States\nand Canada:\n\n\n * Waterfall Scientific (Worcester, MA): prime contractor; continuous-flow RNA\nsynthesis based on its DuoTether™ platform\n\n * Ginkgo Bioworks (Boston, MA, and Emeryville, CA): automation hardware, systems\nintegration, and control software\n\n * Ansa Biotechnologies (Emeryville, CA): enzymatic, cell-free DNA template\nproduction\n\n * Polymorphic Biosciences (Vancouver, BC): lipid nanoparticle (LNP)\nencapsulation\n\n * Tensentric (Boulder, CO): fill and finish, sterility, and device engineering\n\n * Volta Labs (Boston, MA): automation and miniaturization for DNA template\nproduction and characterization\n\nGIVE is administered by ARPA-H’s Scalable Solutions Office, which funds\nprograms intended to improve the speed, scale, and accessibility of medical\ntreatments across the United States. The program is structured in phases,\nbeginning with a design and engineering phase, followed by build, integration,\nand system demonstration. Work is expected to begin with a technical kickoff\nlater this month.\n\nBuilding on a Growing Federal Portfolio\n\nESCALATOR extends Ginkgo’s work with ARPA-H and other federal partners on\nprograms aimed at national health resilience. A small business under many\nfederal size standards, Ginkgo both contributes platform-scale automation,\nsoftware, and biological engineering as a subcontractor to consortia led by\nspecialized innovators, and leads consortia as prime contractor with our\ngrowing systems integration and Government relations experience; ESCALATOR\nrepresents the former model. Our U.S. Government research portfolio\ndemonstrates how federal funds can enable highly focused and innovative\ntechnology companies to access infrastructure they would otherwise need years\nto build.\n\nAbout Ginkgo Bioworks\n\nGinkgo Bioworks builds the tools that make biology easier to engineer for\neveryone. The company offers autonomous laboratories that replace manual\nlaboratory work with robotics in the lab, greatly improving the productivity\nof scientists. Ginkgo's in-house autonomous lab is also available as a \"Cloud\nLab\" through our Datapoints and Solutions contract research services. For more\ninformation, visit ginkgobioworks.com, read our blog, or follow us on social\nmedia channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads\n(@GinkgoBioworks), or LinkedIn.\n\nAbout Waterfall Scientific\n\nWaterfall Scientific is a Massachusetts-based biotechnology platform company\ndeveloping continuous-flow technologies for mRNA manufacturing. Spun out of\nthe University of Massachusetts Amherst with exclusively licensed technology\ndeveloped in the laboratory of Prof. Craig T. Martin, Ph.D, (Waterfall\nScientific CSO and Co-founder), Waterfall Scientific’s DuoTether\ncontinuous-flow system dramatically improves the purity and efficiency of mRNA\nsynthesis. Waterfall welcomes interest from investors in the biomanufacturing\nspace. For more information, visit www.waterfallsci.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.waterfallsci.com&esheet=54601179&newsitemid=20260910477067&lan=en-US&anchor=www.waterfallsci.com&index=1&md5=65b913dcbe25006b7d7f868a3bd4f018)\n.\n\nForward-Looking Statements of Ginkgo Bioworks\n\nThis announcement contains certain forward-looking statements within the\nmeaning of the federal securities laws, including statements regarding the\ncapabilities and potential success of the partnership. These forward-looking\nstatements generally are identified by the words \"believe,\" \"can,\" \"project,\"\n\"potential,\" \"expect,\" \"anticipate,\" \"estimate,\" \"intend,\" \"strategy,\"\n\"future,\" \"opportunity,\" \"plan,\" \"may,\" \"should,\" \"will,\" \"would,\" \"will be,\"\n\"will continue,\" \"will likely result,\" and similar expressions.\nForward-looking statements are predictions, projections and other statements\nabout future events that are based on current expectations and assumptions\nand, as a result, are subject to risks and uncertainties. Many factors could\ncause actual future events to differ materially from the forward-looking\nstatements in this announcement, including but not limited to: (i) our ability\nto realize near-term and long-term cost savings associated with our site\nconsolidation plans, including the ability to terminate leases or find\nsub-lease tenants for unused facilities, (ii) volatility in the price of\nGinkgo's securities due to a variety of factors, including changes in the\ncompetitive and highly regulated industries in which Ginkgo operates and plans\nto operate, variations in performance across competitors, and changes in laws\nand regulations affecting Ginkgo's business, (iii) the ability to implement\nbusiness plans, forecasts, and other expectations, and to identify and realize\nadditional business opportunities, including with respect to our solutions and\ntools offerings, (iv) the risk of downturns in demand for products using\nsynthetic biology, (v) the uncertainty regarding the demand for passive\nmonitoring programs and biosecurity services, (vi) changes to the biosecurity\nindustry, including due to advancements in technology, emerging competition\nand evolution in industry demands, standards and regulations, (vii) the\noutcome of any pending or potential legal proceedings against Ginkgo, (viii)\nour ability to realize the expected benefits from and the success of our\nplatform programs and assets, (ix) our ability to successfully develop\nengineered cells, bioprocesses, data packages or other deliverables, (x) the\nproduct development, production or manufacturing success of our customers,\n(xi) our exposure to the volatility and liquidity risks inherent in holding\nequity interests in other operating companies and other non-cash consideration\nwe may receive for our services, (xii) the potential negative impact on our\nbusiness of our restructuring or the failure to realize the anticipated\nsavings associated therewith, (xiii) the uncertainty regarding government\nbudgetary priorities and funding allocated to government agencies, including\npotential adverse effects from the U.S. government shutdown, (xiv) our ability\nto scale, expand the capacity of, and continue to develop the capabilities of\nour autonomous lab (including Nebula) on the timelines and to the extent we\nanticipate, (xv) the pace and degree to which autonomous laboratory\ninfrastructure is adopted by, and displaces manual laboratory work in, the\nbroader life sciences and industrial biotechnology markets, (xvi) the actual\nsize, composition and growth of the addressable markets we target, which may\ndiffer materially from our estimates, (xvii) our ability to integrate our\nautonomous lab platform with third-party artificial intelligence models and\nother technologies, and the rate of development and adoption of such\ntechnologies, and (xviii) our ability to maintain and expand strategic\npartnerships and customer relationships, including those with named partners\nreferenced in this announcement. The foregoing list of factors is not\nexhaustive. You should carefully consider the foregoing factors and the other\nrisks and uncertainties described in the \"Risk Factors\" section of Ginkgo's\nannual report on Form 10-K filed with the U.S. Securities and Exchange\nCommission (the \"SEC\") on February 26, 2026, and other documents filed by\nGinkgo from time to time with the SEC. These filings identify and address\nother important risks and uncertainties that could cause actual events and\nresults to differ materially from those contained in the forward-looking\nstatements. Forward-looking statements speak only as of the date they are\nmade. Readers are cautioned not to put undue reliance on forward-looking\nstatements, and Ginkgo assumes no obligation and does not intend to update or\nrevise these forward-looking statements, whether as a result of new\ninformation, future events, or otherwise. Ginkgo does not give any assurance\nthat it will achieve its expectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260910477067/en/\n(https://www.businesswire.com/news/home/20260910477067/en/)\n\nMEDIA CONTACT: press@ginkgobioworks.com (mailto:press@ginkgobioworks.com)\n\nINVESTOR CONTACT: investors@ginkgobioworks.com\n(mailto:investors@ginkgobioworks.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5ZmWQwa-20260910","title":"Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines","author":"Business Wire","ticker":"DNA","created":"2026-09-10T12:00:02.212Z","tickers":["DNA"],"exchange":"NYSE","article_body":"Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing\nSystem for Individualized RNA Medicines\n\nGinkgo plans to build the automation hardware and control software for\nESCALATOR, a continuous-flow, autonomous manufacturing system designed to\nproduce and quality-release RNA drug products at patient scale\n\nGinkgo Bioworks (NYSE: DNA) today announced that it has been awarded a\nsubcontract for up to $17.5M under the Advanced Research Projects Agency for\nHealth’s (ARPA-H) Genetic Medicines and Individualized Manufacturing for\nEveryone (GIVE) program. Ginkgo will serve as a subcontractor to prime\ncontractor Waterfall Scientific, Inc. on ESCALATOR (Engineering a Small-scale,\nContinuous-flow manufacturing Apparatus to Launch A Transformational Overhaul\nfor RNA medicines), a multi-organization effort to compress end-to-end RNA\ndrug manufacturing onto a benchtop footprint.\n\nRNA therapeutics designed for a single patient—including individualized\ncancer vaccines and bespoke gene therapies—remain difficult to deliver at\nscale. Production today depends on large, centralized facilities, lengthy\nmanual workflows, and quality control processes that were designed for batch\nsizes far larger than one. The result is a class of medicine that is\nscientifically feasible but logistically out of reach for most patients who\ncould benefit from it.\n\nESCALATOR is designed to change that equation by building a single,\nintegrated, autonomous manufacturing system that accepts a sequence and\nreturns a purified, quality-released RNA drug product at the scale an\nindividual patient requires. The system comprises four custom manufacturing\nmodules: cell-free DNA template production, RNA synthesis, lipid nanoparticle\n(LNP) encapsulation, and fill and finish. These are coupled to an in-line\nquality control subsystem drawing on approximately twenty analytical\ninstruments.\n\nGinkgo’s Role: Making Twenty Instruments Behave as One System\n\nGinkgo is building the layer that turns a collection of instruments into an\nintegrated autonomous manufacturing system and carries the process through to\nan automated quality decision on the finished product. Drawing on its\nReconfigurable Automation Carts (RACs) and Catalyst software, Ginkgo aims to:\n\n\n * Integrate the four custom manufacturing modules and the quality control\ninstrument set into a unified robotic transport platform;\n\n * Extend Catalyst to control the entire system with a unified interface,\nproviding simple local configuration and launching of manufacturing runs,\nremote protocol definition and monitoring, and the data integrity and audit\ntrail expected of GMP manufacturing environments;\n\n * Develop and validate automated protocols for both the manufacturing and\nquality control workflows, including virtual protocol simulation prior to\nhardware execution; and\n\n * Enable Catalyst to rigorously evaluate product quality based on data collected\nby the system and historical benchmarks, escalating to expert review as\nappropriate.\n\n“One of the most challenging parts of ESCALATOR is making instruments from\nsix different organizations behave as one controlled, auditable system that a\ntrained technician can operate without a robotics team standing behind\nthem,” said Jason Kelly, co-founder and CEO at Ginkgo Bioworks. \"Ginkgo has\nspent years building autonomous labs that can work with a variety of hardware\nand with proprietary software that tracks every device for every run.\nDistributed manufacturing has stayed a promise rather than a practice because\nthat layer didn’t exist. We are excited to be deploying it for ESCALATOR.”\n\n\"We are thrilled to lead such an exceptional consortium on this journey to\nmake personalized medicine a reality for patients who cannot wait. Ginkgo\nBioworks brings unmatched hardware and software integration capabilities to\nthe table, and we look forward to building a truly transformative system\ntogether,” said Inna Shcherbakova, co-founder and CEO of Waterfall\nScientific.\n\nA Consortium Assembled Around a Single Integrated System\n\nThe ESCALATOR team brings together six organizations across the United States\nand Canada:\n\n\n * Waterfall Scientific (Worcester, MA): prime contractor; continuous-flow RNA\nsynthesis based on its DuoTether™ platform\n\n * Ginkgo Bioworks (Boston, MA, and Emeryville, CA): automation hardware, systems\nintegration, and control software\n\n * Ansa Biotechnologies (Emeryville, CA): enzymatic, cell-free DNA template\nproduction\n\n * Polymorphic Biosciences (Vancouver, BC): lipid nanoparticle (LNP)\nencapsulation\n\n * Tensentric (Boulder, CO): fill and finish, sterility, and device engineering\n\n * Volta Labs (Boston, MA): automation and miniaturization for DNA template\nproduction and characterization\n\nGIVE is administered by ARPA-H’s Scalable Solutions Office, which funds\nprograms intended to improve the speed, scale, and accessibility of medical\ntreatments across the United States. The program is structured in phases,\nbeginning with a design and engineering phase, followed by build, integration,\nand system demonstration. Work is expected to begin with a technical kickoff\nlater this month.\n\nBuilding on a Growing Federal Portfolio\n\nESCALATOR extends Ginkgo’s work with ARPA-H and other federal partners on\nprograms aimed at national health resilience. A small business under many\nfederal size standards, Ginkgo both contributes platform-scale automation,\nsoftware, and biological engineering as a subcontractor to consortia led by\nspecialized innovators, and leads consortia as prime contractor with our\ngrowing systems integration and Government relations experience; ESCALATOR\nrepresents the former model. Our U.S. Government research portfolio\ndemonstrates how federal funds can enable highly focused and innovative\ntechnology companies to access infrastructure they would otherwise need years\nto build.\n\nAbout Ginkgo Bioworks\n\nGinkgo Bioworks builds the tools that make biology easier to engineer for\neveryone. The company offers autonomous laboratories that replace manual\nlaboratory work with robotics in the lab, greatly improving the productivity\nof scientists. Ginkgo's in-house autonomous lab is also available as a \"Cloud\nLab\" through our Datapoints and Solutions contract research services. For more\ninformation, visit ginkgobioworks.com, read our blog, or follow us on social\nmedia channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads\n(@GinkgoBioworks), or LinkedIn.\n\nAbout Waterfall Scientific\n\nWaterfall Scientific is a Massachusetts-based biotechnology platform company\ndeveloping continuous-flow technologies for mRNA manufacturing. Spun out of\nthe University of Massachusetts Amherst with exclusively licensed technology\ndeveloped in the laboratory of Prof. Craig T. Martin, Ph.D, (Waterfall\nScientific CSO and Co-founder), Waterfall Scientific’s DuoTether\ncontinuous-flow system dramatically improves the purity and efficiency of mRNA\nsynthesis. Waterfall welcomes interest from investors in the biomanufacturing\nspace. For more information, visit www.waterfallsci.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.waterfallsci.com&esheet=54601179&newsitemid=20260910477067&lan=en-US&anchor=www.waterfallsci.com&index=1&md5=65b913dcbe25006b7d7f868a3bd4f018)\n.\n\nForward-Looking Statements of Ginkgo Bioworks\n\nThis announcement contains certain forward-looking statements within the\nmeaning of the federal securities laws, including statements regarding the\ncapabilities and potential success of the partnership. These forward-looking\nstatements generally are identified by the words \"believe,\" \"can,\" \"project,\"\n\"potential,\" \"expect,\" \"anticipate,\" \"estimate,\" \"intend,\" \"strategy,\"\n\"future,\" \"opportunity,\" \"plan,\" \"may,\" \"should,\" \"will,\" \"would,\" \"will be,\"\n\"will continue,\" \"will likely result,\" and similar expressions.\nForward-looking statements are predictions, projections and other statements\nabout future events that are based on current expectations and assumptions\nand, as a result, are subject to risks and uncertainties. Many factors could\ncause actual future events to differ materially from the forward-looking\nstatements in this announcement, including but not limited to: (i) our ability\nto realize near-term and long-term cost savings associated with our site\nconsolidation plans, including the ability to terminate leases or find\nsub-lease tenants for unused facilities, (ii) volatility in the price of\nGinkgo's securities due to a variety of factors, including changes in the\ncompetitive and highly regulated industries in which Ginkgo operates and plans\nto operate, variations in performance across competitors, and changes in laws\nand regulations affecting Ginkgo's business, (iii) the ability to implement\nbusiness plans, forecasts, and other expectations, and to identify and realize\nadditional business opportunities, including with respect to our solutions and\ntools offerings, (iv) the risk of downturns in demand for products using\nsynthetic biology, (v) the uncertainty regarding the demand for passive\nmonitoring programs and biosecurity services, (vi) changes to the biosecurity\nindustry, including due to advancements in technology, emerging competition\nand evolution in industry demands, standards and regulations, (vii) the\noutcome of any pending or potential legal proceedings against Ginkgo, (viii)\nour ability to realize the expected benefits from and the success of our\nplatform programs and assets, (ix) our ability to successfully develop\nengineered cells, bioprocesses, data packages or other deliverables, (x) the\nproduct development, production or manufacturing success of our customers,\n(xi) our exposure to the volatility and liquidity risks inherent in holding\nequity interests in other operating companies and other non-cash consideration\nwe may receive for our services, (xii) the potential negative impact on our\nbusiness of our restructuring or the failure to realize the anticipated\nsavings associated therewith, (xiii) the uncertainty regarding government\nbudgetary priorities and funding allocated to government agencies, including\npotential adverse effects from the U.S. government shutdown, (xiv) our ability\nto scale, expand the capacity of, and continue to develop the capabilities of\nour autonomous lab (including Nebula) on the timelines and to the extent we\nanticipate, (xv) the pace and degree to which autonomous laboratory\ninfrastructure is adopted by, and displaces manual laboratory work in, the\nbroader life sciences and industrial biotechnology markets, (xvi) the actual\nsize, composition and growth of the addressable markets we target, which may\ndiffer materially from our estimates, (xvii) our ability to integrate our\nautonomous lab platform with third-party artificial intelligence models and\nother technologies, and the rate of development and adoption of such\ntechnologies, and (xviii) our ability to maintain and expand strategic\npartnerships and customer relationships, including those with named partners\nreferenced in this announcement. The foregoing list of factors is not\nexhaustive. You should carefully consider the foregoing factors and the other\nrisks and uncertainties described in the \"Risk Factors\" section of Ginkgo's\nannual report on Form 10-K filed with the U.S. Securities and Exchange\nCommission (the \"SEC\") on February 26, 2026, and other documents filed by\nGinkgo from time to time with the SEC. These filings identify and address\nother important risks and uncertainties that could cause actual events and\nresults to differ materially from those contained in the forward-looking\nstatements. Forward-looking statements speak only as of the date they are\nmade. Readers are cautioned not to put undue reliance on forward-looking\nstatements, and Ginkgo assumes no obligation and does not intend to update or\nrevise these forward-looking statements, whether as a result of new\ninformation, future events, or otherwise. Ginkgo does not give any assurance\nthat it will achieve its expectations.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260910477067/en/\n(https://www.businesswire.com/news/home/20260910477067/en/)\n\nMEDIA CONTACT: press@ginkgobioworks.com (mailto:press@ginkgobioworks.com)\n\nINVESTOR CONTACT: investors@ginkgobioworks.com\n(mailto:investors@ginkgobioworks.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-10T12:00:03.0406105Z","server_sent_at_ms":1789041603040},"received_at":"2026-09-10T12:00:03.098Z","source_url":"https://www.businesswire.com/news/home/20260910477067/en/"},"analysis":{"id":"129125","press_release_id":"140308","analysis_json":{"industry":{"label":"Life Sciences Tools & Services","sector":"Health Care"},"redFlags":["Subcontract value is a ceiling ('up to $17.5M') phased across program stages beginning with design/engineering -- not guaranteed revenue","Ginkgo is a subcontractor, not prime, limiting control over program scope and funding","Forward-looking statements flag U.S. government shutdown and federal budgetary priorities as risks to agency funding"],"eventType":"operations_update","narrative":"Ginkgo Bioworks has been awarded a subcontract for up to $17.5M under ARPA-H's GIVE program, serving as a subcontractor to prime contractor Waterfall Scientific on the ESCALATOR project.\n\nESCALATOR aims to compress end-to-end RNA drug manufacturing onto a benchtop footprint, producing and quality-releasing individualized RNA medicines at single-patient scale; Ginkgo will build the automation hardware and Catalyst control software that integrate instruments from six organizations into one autonomous, auditable system.\n\nThe award extends Ginkgo's growing U.S. Government research portfolio and validates its autonomous-lab platform, though the value is a phased ceiling rather than guaranteed near-term revenue.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Modest federal validation: up to $17.5M ARPA-H subcontract for Ginkgo's autonomous-lab platform -- incremental positive, not a needle-mover."},"keyFigures":{"dealValueUsd":17500000,"customDimensions":{"contract_type":"ARPA-H GIVE program subcontract (Ginkgo as subcontractor to prime Waterfall Scientific)","qc_instruments":"approximately twenty analytical instruments","consortium_members":6}},"quotedText":"One of the most challenging parts of ESCALATOR is making instruments from six different organizations behave as one controlled, auditable system that a trained technician can operate without a robotics team standing behind them","namedEntities":{"people":[{"name":"Jason Kelly","role":"co-founder and CEO, Ginkgo Bioworks"},{"name":"Inna Shcherbakova","role":"co-founder and CEO, Waterfall Scientific"},{"name":"Prof. Craig T. Martin, Ph.D","role":"Waterfall Scientific CSO and Co-founder"}],"products":["ESCALATOR","Reconfigurable Automation Carts (RACs)","Catalyst software","DuoTether continuous-flow platform","Cloud Lab"],"companies":[{"name":"Ginkgo Bioworks","ticker":"DNA","relationship":"filer / subcontractor"},{"name":"Waterfall Scientific, Inc.","relationship":"prime contractor"},{"name":"Advanced Research Projects Agency for Health (ARPA-H)","relationship":"funding agency (GIVE program)"},{"name":"Ansa Biotechnologies","relationship":"consortium partner (cell-free DNA template production)"},{"name":"Polymorphic Biosciences","relationship":"consortium partner (LNP encapsulation)"},{"name":"Tensentric","relationship":"consortium partner (fill and finish, device engineering)"},{"name":"Volta Labs","relationship":"consortium partner (DNA template automation)"}],"dollarAmounts":[{"amount":"$17.5M","context":"subcontract award ceiling under ARPA-H GIVE program"}]},"materialImpact":{"score":2,"reasoning":"A contract win: Ginkgo secured a subcontract worth up to $17.5M under ARPA-H's GIVE program, a positive but incremental federal award. The value is a phased ceiling ('up to'), Ginkgo is a subcontractor rather than prime, and the figure is modest relative to Ginkgo's annual revenue base."},"tickerRelevance":{"others":[],"primary":"DNA"},"globalImportance":22,"audienceRelevance":32,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"small-cap with retail following","eventGravity":"federal subcontract award (up to $17.5M)","sectorWeight":"biotech platform / government-funded R&D","issuerAuthored":true,"contractCertainty":"ceiling value, phased program","retailFavoriteBoost":"moderate"}},"event_type":"operations_update","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":2,"narrative":"Ginkgo Bioworks has been awarded a subcontract for up to $17.5M under ARPA-H's GIVE program, serving as a subcontractor to prime contractor Waterfall Scientific on the ESCALATOR project.\n\nESCALATOR aims to compress end-to-end RNA drug manufacturing onto a benchtop footprint, producing and quality-releasing individualized RNA medicines at single-patient scale; Ginkgo will build the automation hardware and Catalyst control software that integrate instruments from six organizations into one autonomous, auditable system.\n\nThe award extends Ginkgo's growing U.S. Government research portfolio and validates its autonomous-lab platform, though the value is a phased ceiling rather than guaranteed near-term revenue.","key_figures":{"dealValueUsd":17500000,"customDimensions":{"contract_type":"ARPA-H GIVE program subcontract (Ginkgo as subcontractor to prime Waterfall Scientific)","qc_instruments":"approximately twenty analytical instruments","consortium_members":6}},"named_entities":{"people":[{"name":"Jason Kelly","role":"co-founder and CEO, Ginkgo Bioworks"},{"name":"Inna Shcherbakova","role":"co-founder and CEO, Waterfall Scientific"},{"name":"Prof. Craig T. Martin, Ph.D","role":"Waterfall Scientific CSO and Co-founder"}],"products":["ESCALATOR","Reconfigurable Automation Carts (RACs)","Catalyst software","DuoTether continuous-flow platform","Cloud Lab"],"companies":[{"name":"Ginkgo Bioworks","ticker":"DNA","relationship":"filer / subcontractor"},{"name":"Waterfall Scientific, Inc.","relationship":"prime contractor"},{"name":"Advanced Research Projects Agency for Health (ARPA-H)","relationship":"funding agency (GIVE program)"},{"name":"Ansa Biotechnologies","relationship":"consortium partner (cell-free DNA template production)"},{"name":"Polymorphic Biosciences","relationship":"consortium partner (LNP encapsulation)"},{"name":"Tensentric","relationship":"consortium partner (fill and finish, device engineering)"},{"name":"Volta Labs","relationship":"consortium partner (DNA template automation)"}],"dollarAmounts":[{"amount":"$17.5M","context":"subcontract award ceiling under ARPA-H GIVE program"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-10T12:02:26.707Z","global_importance":22,"audience_relevance":32,"importance_components":{"tickerTier":"small-cap with retail following","eventGravity":"federal subcontract award (up to $17.5M)","sectorWeight":"biotech platform / government-funded R&D","issuerAuthored":true,"contractCertainty":"ceiling value, phased program","retailFavoriteBoost":"moderate"}},"durationMs":36426,"modelName":"glm-5.3-flash"}}